Conway Capital Management Inc. Boosts Stock Holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Conway Capital Management Inc. increased its position in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 13.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 161,225 shares of the company's stock after purchasing an additional 19,725 shares during the period. ClearPoint Neuro makes up 1.1% of Conway Capital Management Inc.'s investment portfolio, making the stock its 19th largest holding. Conway Capital Management Inc. owned about 0.58% of ClearPoint Neuro worth $2,480,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Point72 DIFC Ltd bought a new stake in ClearPoint Neuro during the 2nd quarter worth approximately $32,000. Barclays PLC boosted its position in shares of ClearPoint Neuro by 24.3% during the third quarter. Barclays PLC now owns 5,674 shares of the company's stock valued at $64,000 after buying an additional 1,109 shares during the last quarter. XTX Topco Ltd grew its holdings in ClearPoint Neuro by 11.6% during the second quarter. XTX Topco Ltd now owns 13,010 shares of the company's stock worth $70,000 after buying an additional 1,353 shares in the last quarter. JPMorgan Chase & Co. raised its position in ClearPoint Neuro by 58.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company's stock valued at $110,000 after buying an additional 3,612 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in ClearPoint Neuro during the 3rd quarter valued at $123,000. 30.08% of the stock is currently owned by institutional investors.

ClearPoint Neuro Price Performance

Shares of NASDAQ CLPT traded up $0.07 during midday trading on Friday, reaching $17.85. The company's stock had a trading volume of 192,618 shares, compared to its average volume of 229,575. The stock has a market capitalization of $492.30 million, a P/E ratio of -25.87 and a beta of 1.01. The firm has a 50 day moving average price of $14.61 and a 200-day moving average price of $12.09. ClearPoint Neuro, Inc. has a 12-month low of $5.11 and a 12-month high of $19.00.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. The business had revenue of $8.12 million during the quarter, compared to analysts' expectations of $8.07 million. During the same period in the prior year, the firm posted ($0.20) EPS. On average, equities analysts predict that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital upped their target price on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the stock a "buy" rating in a research note on Tuesday.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.